IDH1 and glioblastoma: Upon metabolic profiling of innate IDH1-mutant GBM cells, Tateishi et al. (2015) observed increases in the NAD+ level with IDH1i treatment and decreases in the NAD+ level compared to IDH1-wildtype cells because of methylation of the NAPRT1 promoter [45].